← All trials
NCT06708520
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Nov 27, 2024
- Last posted
- Nov 27, 2024
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Noucor Health S.A.Lead sponsor
- Badalona Hospital Germans Trias i PujolOfficial
- University of BarcelonaOfficial
- Centro Hospitalar de Vila Nova de Gaia/EspinhoOfficial
- Hospital Pedro HispanoOfficial
- Blueclinical Investigacao E Desenvolvimento Em Saude Lda.Official
- Universidad Autonoma de MadridOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.